TY - JOUR PY - 2005 DA - 2005// TI - Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials JO - Lancet. VL - 365 UR - https://doi.org/10.1016/S0140-6736(05)66544-0 DO - 10.1016/S0140-6736(05)66544-0 ID - ref1 ER - TY - JOUR AU - Paik, S. AU - Shak, S. AU - Tang, G. AU - Kim, C. AU - Baker, J. AU - Cronin, M. PY - 2004 DA - 2004// TI - A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer JO - N Engl J Med VL - 351 UR - https://doi.org/10.1056/NEJMoa041588 DO - 10.1056/NEJMoa041588 ID - Paik2004 ER - TY - JOUR AU - Paik, S. AU - Tang, G. AU - Shak, S. AU - Kim, C. AU - Baker, J. AU - Kim, W. PY - 2006 DA - 2006// TI - Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.04.7985 DO - 10.1200/JCO.2005.04.7985 ID - Paik2006 ER - TY - JOUR AU - Geyer, C. E. AU - Tang, G. AU - Mamounas, E. P. AU - Rastogi, P. AU - Paik, S. AU - Shak, S. PY - 2018 DA - 2018// TI - 21-gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer JO - NPJ Breast Cancer. VL - 4 UR - https://doi.org/10.1038/s41523-018-0090-6 DO - 10.1038/s41523-018-0090-6 ID - Geyer2018 ER - TY - JOUR AU - Sparano, J. A. AU - Gray, R. J. AU - Makower, D. F. AU - Pritchard, K. I. AU - Albain, K. S. AU - Hayes, D. F. PY - 2015 DA - 2015// TI - Prospective validation of a 21-gene expression assay in breast cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510764 DO - 10.1056/NEJMoa1510764 ID - Sparano2015 ER - TY - JOUR AU - Sparano, J. A. AU - Gray, R. J. AU - Makower, D. F. AU - Pritchard, K. I. AU - Albain, K. S. AU - Hayes, D. F. PY - 2018 DA - 2018// TI - Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1804710 DO - 10.1056/NEJMoa1804710 ID - Sparano2018 ER - TY - JOUR AU - Stemmer, S. M. AU - Steiner, M. AU - Rizel, S. AU - Soussan-Gutman, L. AU - Ben-Baruch, N. AU - Bareket-Samish, A. PY - 2017 DA - 2017// TI - Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry JO - NPJ Breast Cancer. VL - 3 UR - https://doi.org/10.1038/s41523-017-0034-6 DO - 10.1038/s41523-017-0034-6 ID - Stemmer2017 ER - TY - JOUR AU - Gluz, O. AU - Nitz, U. A. AU - Christgen, M. AU - Kates, R. E. AU - Shak, S. AU - Clemens, M. PY - 2016 DA - 2016// TI - West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.63.5383 DO - 10.1200/JCO.2015.63.5383 ID - Gluz2016 ER - TY - JOUR AU - Ibraheem, A. F. AU - Press, D. J. AU - Olopade, O. I. AU - Huo, D. PY - 2019 DA - 2019// TI - Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: who benefits from chemotherapy? JO - Cancer. VL - 125 UR - https://doi.org/10.1002/cncr.31818 DO - 10.1002/cncr.31818 ID - Ibraheem2019 ER - TY - STD TI - NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer; Version 3.2018. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 10 Dec 2018. UR - https://www.nccn.org/professionals/physician_gls/default.aspx ID - ref10 ER - TY - JOUR AU - Petkov, V. I. AU - Miller, D. P. AU - Howlader, N. AU - Gliner, N. AU - Howe, W. AU - Schussler, N. PY - 2016 DA - 2016// TI - Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study JO - NPJ Breast Cancer VL - 2 UR - https://doi.org/10.1038/npjbcancer.2016.17 DO - 10.1038/npjbcancer.2016.17 ID - Petkov2016 ER - TY - JOUR AU - Johnson, C. J. AU - Weir, H. K. AU - Fink, A. K. AU - German, R. R. AU - Finch, J. L. AU - Rycroft, R. K. PY - 2013 DA - 2013// TI - The impact of National Death Index linkages on population-based cancer survival rates in the United States JO - Cancer Epidemiol VL - 37 UR - https://doi.org/10.1016/j.canep.2012.08.007 DO - 10.1016/j.canep.2012.08.007 ID - Johnson2013 ER - TY - JOUR AU - Sparano, J. A. PY - 2006 DA - 2006// TI - TAILORx: trial assigning individualized options for treatment (Rx) JO - Clin Breast Cancer VL - 7 UR - https://doi.org/10.3816/CBC.2006.n.051 DO - 10.3816/CBC.2006.n.051 ID - Sparano2006 ER - TY - JOUR AU - Curigliano, G. AU - Burstein, H. J. AU - E, P. W. AU - Gnant, M. AU - Dubsky, P. AU - Loibl, S. PY - 2017 DA - 2017// TI - De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx308 DO - 10.1093/annonc/mdx308 ID - Curigliano2017 ER - TY - JOUR AU - Nitz, U. AU - Gluz, O. AU - Christgen, M. AU - Kates, R. E. AU - Clemens, M. AU - Malter, W. PY - 2017 DA - 2017// TI - Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial JO - Breast Cancer Res Treat VL - 165 UR - https://doi.org/10.1007/s10549-017-4358-6 DO - 10.1007/s10549-017-4358-6 ID - Nitz2017 ER - TY - JOUR AU - Jasem, J. AU - Amini, A. AU - Rabinovitch, R. AU - Borges, V. F. AU - Elias, A. AU - Fisher, C. M. PY - 2016 DA - 2016// TI - 21-gene recurrence score assay as a predictor of adjuvant chemotherapy administration for early-stage breast cancer: an analysis of use, therapeutic implications, and disparity profile JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.65.0887 DO - 10.1200/JCO.2015.65.0887 ID - Jasem2016 ER - TY - JOUR AU - Williams, A. D. AU - Reyes, S. A. AU - Arlow, R. L. AU - Tchou, J. AU - Cruz, L. M. PY - 2018 DA - 2018// TI - Is age trumping genetic profiling in clinical practice? Relationship of chemotherapy recommendation and Oncotype DX recurrence score in patients aged < 50 years versus ≥ 50 years, and trends over time JO - Ann Surg Oncol VL - 25 UR - https://doi.org/10.1245/s10434-018-6600-9 DO - 10.1245/s10434-018-6600-9 ID - Williams2018 ER - TY - JOUR AU - Toi, M. AU - Iwata, H. AU - Yamanaka, T. AU - Masuda, N. AU - Ohno, S. AU - Nakamura, S. PY - 2010 DA - 2010// TI - Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population JO - Cancer. VL - 116 UR - https://doi.org/10.1002/cncr.25206 DO - 10.1002/cncr.25206 ID - Toi2010 ER - TY - JOUR AU - Lee, M. H. AU - Han, W. AU - Lee, J. E. AU - Kim, K. S. AU - Park, H. AU - Kim, J. PY - 2015 DA - 2015// TI - The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea JO - Cancer Res Treat VL - 47 UR - https://doi.org/10.4143/crt.2013.223 DO - 10.4143/crt.2013.223 ID - Lee2015 ER - TY - JOUR AU - Kozick, Z. AU - Hashmi, A. AU - Dove, J. AU - Hunsinger, M. AU - Arora, T. AU - Wild, J. PY - 2018 DA - 2018// TI - Disparities in compliance with the Oncotype DX breast cancer test in the United States: a National Cancer Data Base assessment JO - Am J Surg VL - 215 UR - https://doi.org/10.1016/j.amjsurg.2017.05.008 DO - 10.1016/j.amjsurg.2017.05.008 ID - Kozick2018 ER - TY - STD TI - Noone A, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al: SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. UR - https://seer.cancer.gov/csr/1975_2015/ ID - ref21 ER - TY - JOUR AU - Noone, A. M. AU - Lund, J. L. AU - Mariotto, A. AU - Cronin, K. AU - McNeel, T. AU - Deapen, D. PY - 2016 DA - 2016// TI - Comparison of SEER treatment data with Medicare claims JO - Med Care VL - 54 UR - https://doi.org/10.1097/MLR.0000000000000073 DO - 10.1097/MLR.0000000000000073 ID - Noone2016 ER -